ReportThe impact of psoriasis on health care costs and patient work loss
Section snippets
Data source
De-identified health and disability administrative claims data were used to assess the incremental cost burden associated with psoriasis. The administrative claims data cover the period January 1, 1998, through January 31, 2005, and include approximately 5.1 million employees, their spouses, and dependents from 31 large, self-insured Fortune 500 US companies. Collectively, these 31 companies have operations throughout the United States and represent a broad array of industries, including
Patient characteristics
Table I summarizes the inclusion criteria used to construct the psoriasis group. For the analysis of direct medical costs, a total of 12,280 patients with psoriasis were matched with 36,840 control subjects. For the analysis of indirect work loss costs, only active employees with work loss data were analyzed, which resulted in 3097 patients with psoriasis and 8335 control subjects.
Table II compares the mean characteristics of the psoriasis group with those of the matched control group. The
Discussion
This study provides evidence that psoriasis represents a substantial direct and indirect cost burden in the United States. Focusing specifically on a large sample of claims from 31 Fortune 500 employer-payers for the period 1998 to 2005, we estimated the incremental direct and indirect costs of psoriasis to be $5508 per patient per year using a univariate matched control analysis, and $1497 per patient per year using multivariate analysis that also controlled for the presence of comorbidities
References (21)
- et al.
Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients
Atherosclerosis
(2007) - et al.
Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
J Investig Dermatol Symp Proc
(2004) - et al.
The direct cost of care for psoriasis and psoriatic arthritis in the United States
J Am Acad Dermatol
(2002) - et al.
Psoriasis, its treatment, and cancer in a cohort of Finnish patients
J Invest Dermatol
(2000) - et al.
Prevalence of cardiovascular risk factors in patients with psoriasis
J Am Acad Dermatol
(2006) - et al.
Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs
J Am Acad Dermatol
(2006) - et al.
Estimating log models: to transform or not to transform
J Health Econ
(2001) - et al.
The burden of selected digestive diseases in the United States
Gastroenterology
(2002) - et al.
Psoriasis causes as much disability as other major medical diseases
J Am Acad Dermatol
(1999) - et al.
Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective
J Am Acad Dermatol
(2006)
Cited by (126)
Out-of-pocket costs for patients with psoriasis in an outpatient dermatology referral service
2021, Anais Brasileiros de DermatologiaHLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis
2019, Journal of Allergy and Clinical ImmunologyJoint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
2019, Journal of the American Academy of DermatologyCitation Excerpt :Persons with moderate or severe disease missed significantly more time from work than those with mild disease.140 Fowler et al estimated that the annual cost of lost work productivity for psoriasis patients was $5508 per patient.141 Whether treatment of psoriasis with particular medications could positively affect a patient's work abilities has been studied.
Psoriasis: Psychosomatic, somatopsychic, or both?
2018, Clinics in DermatologyResistin–A Plausible Therapeutic Target in the Pathogenesis of Psoriasis
2024, Immunological InvestigationsThe Rate of Social Acceptance in Psoriasis Patients: A Cross- Sectional Study in Iran
2023, Journal of Iranian Medical Council
Supported by Novartis Pharmaceuticals Corp.
Disclosure: Dr Swensen, Dr Sung, Mr Doyle, and Dr Lobo are employees of and Dr Fowler, Dr Duh, Dr Rovba, Ms Buteau, Ms Pinheiro, Mr Mallett, and Dr Kosicki are consultants to Novartis Pharmaceuticals Corp.
Presented in part at the following poster sessions: 65th Annual Meeting of the American Academy of Dermatology, Washington, DC, February 2-6, 2007, and 12th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, VA, May 19-23, 2007.